Metoprolol in acute myocardial infarction. Enzymatic estimation of infarct size. The MIAMI Trial Research Group.
The maximum serum activity for aspartate aminotransferase (s-ASAT) during the first 3 days was recorded in 5,507 patients with suspected or definite acute myocardial infarction. The s-ASAT activity was corrected for the normal range from each center. The median s-ASAT activity was 4.9 arbitrary units in the placebo group versus 4.6 arbitrary units in the metoprolol group (p = 0.072). Univariate analyses indicated that the delay time between onset of symptoms and randomization and sympathetic activity at entry significantly influenced the effect of metoprolol. A similar decrease in serum enzyme activity after metoprolol treatment was observed independent of signs of infarct localization on the entry electrocardiogram.
D001219:Aspartate Aminotransferases / Q000097:blood; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D006339:Heart Rate; D006801:Humans; D007527:Isoenzymes; D008790:Metoprolol / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors
D007527:Isoenzymes; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D008790:Metoprolol